Catalyst Wire Dossier Catalyst Wire Dossier

Onvansertib

onvansertib
Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for Onvansertib, covering 2023-02-27 to 2026-02-23. Get the full timeline:

Most recent: Clinical Trial Update: Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms [Phase 1]

See pricing